Abstract
Mantle cell lymphoma is included in the World Health Organization classification as distinct lymphoma subtype characterized by the t(11;14)(q13;q32) translocation,which results in overexpression of Cyclin D1.The clinical presentation often includes extranodal involvement,particularly of the bone marrow and gut.The prognosis of patients with mantle cell lymphoma (median overall survival,3-5 years) is poorest among B-cell lymphoma patients,even though a prospectively difficult to identify subgroup can survive for vears with little or no treatment. Conventional chemotherapy is not curative but obtains frequent remissions (60%-90%) which are usually shorter (1-2 years) compared with other lymphoma entities.Very intensive regimens,including autologous and allogeneic stem cell transplantation,seem required to improve the outcome,but with the median age of diagnosis being 60 years or more,such approaches are feasible only in a limited proportion of patients.The possibility of treating patients based on prognostic factors needs to be investigated prospectively. Key words: Lymphoma,mantle cell; Histology; Treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
